Skip to main content
SpringerLink
Log in

5-aminosalicylic acid preparations in the treatment of inflammatory bowel disease

  • Published:
InflammoPharmacology Aims and scope Submit manuscript

Abstract

Multiple new 5-aminosalicylic acid preparations have joined sulphasalazine in our armamentarium of agents for the treatment of inflammatory bowel disease. Rowasa enemas are clearly an advance in our ability to treat distal ulcerative colitis. Oral 5-ASA analogues are equivalent to sulphasalazine in maintaining ulcerative colitis in remission but may have some increased efficacy in high doses for treating mild to moderate active ulcerative colitis. These agents are particularly useful in the sulphasalazine-intolerant individual. Some of the new 5-ASA preparations have been found to be helpful in the treatment of active Crohn’s disease. There is hope that the newer agents having distal small bowel drug release may be beneficial in maintaining Crohn’s disease in remission.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Svartz N. Salazopyrin, a new sulphanilamide preparation. A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulphanilamide preparations. Acta Med Scand. 1942;110:577–98.

    Article  Google Scholar 

  2. Svartz N. The treatment of 124 cases of ulcerative colitis with salazopyrin and attempts of desensibilization in case of hypersensitiveness to sulfa. Acta Med Scand. 1948;130(suppl 206):465–72.

    Google Scholar 

  3. Azad Khan AR, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977;2:892–5.

    Google Scholar 

  4. Van Hees PAM, Bakker JH, Van Tongeren JHM. Effect of sulphapyridine, 5-aminosalicylic acid and placebo in patients with idiopathic proctitis; A study to determine the active therapeutic moeity of sulphasalazine. Gut. 1980;21:632–5.

    PubMed  Google Scholar 

  5. Campieri M, Lanfranchi GA, Bazzochi G et al. Treatment of ulcerative colitis with high dose 5-aminosalicylic acid enemas. Lancet. 1981;2:270–1.

    Article  PubMed  CAS  Google Scholar 

  6. Taffet SL, Das KM. Sulphasalazine - adverse effects and desensitization. Dig Dis Sci. 1983;28:833–42.

    Article  PubMed  CAS  Google Scholar 

  7. Sandberg-Gertzen H, Ryde M, Jarnerot G. Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy. Scand J Gastroenterol. 1983;18:107–11.

    Article  PubMed  CAS  Google Scholar 

  8. Willoughby CP, Aronsson JK, Agback H, Bodin NO, Truelove SC. Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut. 1982;23:1081–7.

    PubMed  CAS  Google Scholar 

  9. Dew MJ, Hughes PJ, Lee MG, Evans BK, Rhodes J. An oral preparation to release drugs in the human colon. Br J Clin Pharmacol. 1982;14:405–8.

    PubMed  CAS  Google Scholar 

  10. Dew MJ, Ryder REJ, Evans N, Evans BK, Rhodes J. Colonie release of 5-ASA from an oral preparation in active ulcerative colitis. Br J Clin Pharmacol. 1983;15:185–7.

    Google Scholar 

  11. Hardy JG, Healy JNC, Reynolds JR. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 1987;1:273–80.

    Article  PubMed  Google Scholar 

  12. Nozlander B, Gotthard R, Strom M. Steady-state pharmacokinetics of enteric coated 5-aminosalicylic acid tablets in healthy volunteers and in patients with Crohn’s disease or ulcerative colitis. Aliment Pharmacol Ther. 1991;5:291–300.

    Article  Google Scholar 

  13. McLeod RS, Cohen Z, Vari BJ, Blair JE, Greenberg GR. The release profile of a controlled release preparation 5-aminosalicylic acid (Rowasa I) in humans. Dis Colon Rectum. 1990;33:21–5.

    Article  PubMed  CAS  Google Scholar 

  14. Rasmussen SN, Bondesen S, Hvidberg EF et al. 5-Aminosalicylic acid in a slow-release preparation: bioavailability, plasma levels, and excretion in humans. Gastroenterology. 1982;83:1062–70.

    PubMed  CAS  Google Scholar 

  15. Chan RD, Pope D, Gilberg AP, Sacra PJ, Barron JH, Lennard-Jones JE. Studies of two novel sulphasalazine analogues ispalazine and balsalizide. Dig Dis Sci. 1983;28:609–15.

    Article  PubMed  CAS  Google Scholar 

  16. Giaffer MH, O’Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment Pharmacol Ther. 1992;6:51–9.

    Article  PubMed  CAS  Google Scholar 

  17. Ginsberg AL, Davis ND, Nochomovitz LF. Placebo-controlled trial of ulcerative colitis with oral 4-aminosalicylic acid. Gastroenterology. 1992;102:448–52.

    PubMed  CAS  Google Scholar 

  18. Campieri M, Lanfranchi GA, Brignola C et al. Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis. Dis Colon Rectum. 1986;29:108–10.

    Article  PubMed  CAS  Google Scholar 

  19. Chapman NJ, Brown ML, Phillips SF et al. Distribution of mesalamine enemas in patients with active distal ulcerative colitis. Mayo Clin Proc. 1992:67:245–8.

    PubMed  CAS  Google Scholar 

  20. Williams CN. Efficacy and tolerance of 5-aminosalicylic acid suppositories in the treatment of ulcerative proctitis: A review of two double-blind, placebo controlled trials. Can J Gastroenterol. 1990;4:472–5.

    Google Scholar 

  21. Selby WS, Bennett MK, Jewell DP. Topical treatment of distal ulcerative colitis with 4-amino-salicylic acid enemas. Digestion. 1984;29:231–4.

    PubMed  CAS  Google Scholar 

  22. Ginsberg AL, Beck LS, Mclntosh TM, Nochomovitz LE. Treatment of left-sided ulcerative colitis with 4-amino acid enemas. Ann Intern Med. 1988;108:195–9.

    PubMed  CAS  Google Scholar 

  23. Lobos EA, Sharon P, Stenson WF. Chemotactic activity in inflammatory bowel disease. Dig Dis Sci. 1987;32:1380–8.

    Article  PubMed  CAS  Google Scholar 

  24. Sharon P, Stenson WF. Enhanced synthesis of leukotriene B4 by colonie mucosa in inflammatory bowel disease. Gastroenterology. 1984;86:453–60.

    PubMed  CAS  Google Scholar 

  25. Nielson OH, Bukhave K, Elmgreen J, Ahnfelt-Ronne I. Inhibition of 5-lipoxygenase pathway of arachidonomic acid metabolism in human neutrophils by sulphasalazine and 5-aminosalicylic acid. Dig Dis Sci. 1987;32:577–82.

    Article  Google Scholar 

  26. Stenson WF, Lobo E. Sulphasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest. 1982;69:494–7.

    PubMed  CAS  Google Scholar 

  27. Ahnfelt-Ronne I, Nielson OH, Christensen A et al. Clinical evidence supporting the radical scavenger mechanism of 5-ASA. Gastroenterology. 1990;98:1162–9.

    PubMed  CAS  Google Scholar 

  28. Allgayer H, Hofer P, Schmidt M, Bohne P, Kruis W, Gugler R. Superoxide, hydroxyl and fatty acid radical scavenging by aminosalicylates. Direct evaluation with electron spin resonance spectroscopy. Biochem Pharmacol. 1992;43:259–62.

    Article  PubMed  CAS  Google Scholar 

  29. Verspaget HW, Aparicio-Pages MN, Ververs S et al. Influence of sulphasalazine and mesalazine on cellular and biochemical oxygen metabolite production. Effect of in vivo administration and an in vitro analysis. Scand J Gastroenterol. 1991;26:779–86.

    PubMed  CAS  Google Scholar 

  30. Myachi Y, Yoshioka A, Imamura S, Niwa Y. Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species. Gut. 1987;28:190–5.

    Google Scholar 

  31. Eliakin R, Kameli F, Razin E, Rachmilewitz D. Role of platelet activating factor in ulcerative colitis. Gastroenterology. 1988;95:1167–72.

    Google Scholar 

  32. Pullman WE, Doe WF. IL-2 production by intestinal lamina propria cells in normal, inflamed, and cancer-bearing colons. Clin Exp Immunol. 1992;88:132–7.

    Article  PubMed  CAS  Google Scholar 

  33. Fox CC, Moore WC, Lichtenstein LM. Modulation of mediator release from human intestinal mast cells by sulphasalazine and 5-aminosalicylic acid. Dig Dis Sci. 1991;36:179–84.

    Article  PubMed  CAS  Google Scholar 

  34. Sutherland LR, Martin F, Greer S et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, protosigmoiditis, and proctitis. Gastroenterology. 1987;92:1894–8.

    PubMed  CAS  Google Scholar 

  35. Willoughby CP, Campieri M, Langranchi G, Truelove SC, Jewell DP. 5-Aminosalicylic acid (Pentasa) in enema form for the treatment of active ulcerative colitis. Ital J Gastroenterol. 1986;18:15–7.

    Google Scholar 

  36. Danish 5-ASA Group. Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. Dig Dis Sci. 1987;32:598–602.

    Article  Google Scholar 

  37. Friedman LS, Richter JM, Kirkham SE, DeMonaco HJ, May RJ. 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial. Am J Gastroenterol. 1986;81:412–8.

    PubMed  CAS  Google Scholar 

  38. McPhee MS, Swan JT, Biddle WL, Greenberger NJ. Proctocolitis unresponsive to conventional therapy. Response to 5-aminosalicylic acid enemas. Dig Dis Sci. 1987;32:765–815.

    Article  Google Scholar 

  39. Guarino J, Chatzinoff M, Berk T, Friedman LS. 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: long-term results. Am J Gastroenterol. 1987;82:732–7.

    PubMed  CAS  Google Scholar 

  40. Biddle WL, Miner PB. Long-term use of mesalamine enemas to induce remission in ulcerative colitis. Gastroenterology. 1990;99:113–8.

    PubMed  CAS  Google Scholar 

  41. Campieri M, Gionchetti P, Belluzzi A et al. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut. 1991;32:929–31.

    PubMed  CAS  Google Scholar 

  42. Campieri M, Gronchetti P, Belluzzi A et al. 5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis. J Clin Gastroenterol. 1988;10:406–9.

    Article  PubMed  CAS  Google Scholar 

  43. Williams CN, Haber G, Aguino JA. Double-blind placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent spread using99MTc-labelled 5-ASA suppositories. Dig Dis Sci. 1987;32:715–55.

    Article  Google Scholar 

  44. Campieri M, Lanfranchi GA, Bertoni F et al. A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis. Digestion. 1984;29:204–8.

    Article  PubMed  CAS  Google Scholar 

  45. Ginsberg AL, Beck LS, Mclntosch TM, Nochomovitz LE. Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas. Ann Intern Med. 1988;108:195–9.

    PubMed  CAS  Google Scholar 

  46. Dick AP, Grayson MJ, Carpenter RG, Petrie A. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut. 1964;5:437–42.

    PubMed  CAS  Google Scholar 

  47. Habal FM, Greenberg GR. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulphasalazine. Am J Gastroenterol. 1988;83:15–7.

    PubMed  CAS  Google Scholar 

  48. Sninsky CA, Cort OH, Shanahan F et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. Ann Intern Med. 1991;115:350–5.

    PubMed  CAS  Google Scholar 

  49. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated orat 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med. 1987;317:1625–9.

    Article  PubMed  CAS  Google Scholar 

  50. Riley SA, Mani V, Goodman MJ, Herd ME, Dult S,Turnberg LA. Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut. 1988;29:669–74.

    PubMed  CAS  Google Scholar 

  51. Meyers S, Sachar DB, Present DH, Janowitz HD. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulphasalazine. Gastroenterology. 1987;93:1255–62.

    PubMed  CAS  Google Scholar 

  52. Selby WS, Barr GD, Ireland A, Mason CH, Jewell DP. Olsalazine in active ulcerative colitis. Br Med J. 1985;291:1373–5.

    CAS  Google Scholar 

  53. Rijk MC, Van Tongeren JH. The efficacy and safety of sulphasalazine and olsalazine in patients with active ulcerative colitis. Gastroenterology. 1991;100:AA243.

    Google Scholar 

  54. Hanauer S, Beshears L, Wilkinson C et al. Induction of remission in a dose-ranging study of oral mesalamine capsules (Pentasa). Gastroenterology. 1990;98:A174.

    Google Scholar 

  55. Miner P, Nostrant T, Wruble L et al. Multicenter trial of Pentasa for active ulcerative colitis. Gastroenterology. 1991;100:A231.

    Google Scholar 

  56. Hanauer SB, Schwartz J, Roufail W et al. Dose-ranging study of oral mesalamine capsules (Pentasa) for active ulcerative colitis. Gastroenterology. 1989;96:A195.

    Google Scholar 

  57. Rachmilewitz D with international study group. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br Med J. 1989,298:82–6.

    CAS  Google Scholar 

  58. Sutherland LR, Robinson M, Onstad G et al. A double-blind placebo-controlled multicentre study of the efficacy and safety of 5-aminosalicylic acid (5-ASA, Rowasa) tablets in the treatment of ulcerative colitis. Can J Gastroenterol. 1990;4:463–7.

    Google Scholar 

  59. Nester T, Borgen L and the Rowasa Study Group. A double-blind comparison of controlled release mesalamine tablets and sulphasalazine (SAS) in the treatment of ulcerative colitis. Gastroenterology. 1992;102:A630.

    Google Scholar 

  60. Miner PB, Biddle WL. Maintaining remission in distal ulcerative colitis and ulcerative proctitis. Can Gastroenterol. 1990;4:476–80.

    Google Scholar 

  61. Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine. Gut. 1973;14:923–6.

    PubMed  CAS  Google Scholar 

  62. Lennard-Jones JE, Connell AM, Baron JH, Jones FA. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet. 1965;1:185.

    Google Scholar 

  63. Azad-Khan AK, Howes DT, Paris J et al. Optimum dose of sulphasalazine for maintenance therapy in ulcerative colitis. Gut. 1980;21:232–40.

    PubMed  CAS  Google Scholar 

  64. Dew MJ, Hughes P, Harries AD, Williams G, Evans BK, Rhodes J. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Br Med J. 1982;285:1012.

    CAS  Google Scholar 

  65. Dew MJ, Harries AD, Evans N, Evans BK, Rhodes J. Maintenance of remission in ulcerative colitis with S-amino salicylic acid in high doses by mouth. Br Med J. 1983;287:23–4.

    CAS  Google Scholar 

  66. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed-release 5-amino salicylic acid (mesalazine) and sulphasalazine as maintenace treatment for patients with ulcerative colitis. Gastroenterology. 1988;94:1383–9.

    PubMed  CAS  Google Scholar 

  67. Sandberg-Gerzen H, Jarnerot G, Kraaz W. Azodisal sodium in the treatment of ulcerative colitis. Gastroenterology. 1986;90:1024–30.

    Google Scholar 

  68. Ireland A, Mason CH, Jewell DP. Controlled trial comparing olsazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut. 1988;29:835–7.

    PubMed  CAS  Google Scholar 

  69. Sandberg-Gertzen H, Jarnerot G, Tysk C. Long-term treatment with olsalazine for ulcerative colitis: safety and relapse prevention. A follow-up study. Scand J Gastroenterol. 1988;23:48–50.

    Google Scholar 

  70. Rijk MC, Van Lier HJ, Van Tongeren JHM. Relapse preventing effect and safety of sulphasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized, multicenter study. Am J Gastroenterol. 1992;87:438–42.

    PubMed  CAS  Google Scholar 

  71. Kiilerich S, Ladefoged K, Rannem T, Ranlov PJ and the Danish Olsalazine Study Group. Prophylactic effects of olsalazine versus sulphasalazinc during 12 months’ maintenance treatment of ulcerative colitis. Gut. 1992;33:252–5.

    PubMed  CAS  Google Scholar 

  72. Kruis W, Judmaier G, Kayasseh L et al. Double-blind dose finding study of olsalazine vs. sulphasalazine for maintenance therapy of ulcerative colitis. Gastroenterology. 1992;102:A648.

    Google Scholar 

  73. Courtney MG, Nunes DP, Bergin CF et al. Randomized comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet. 1992;339:1279–81.

    Article  PubMed  CAS  Google Scholar 

  74. Beshears L, Hanauer S, Guernsey B et al. Open-label study of oral mesalamine capsules (Pentasa) for the treatment of ulcerative colitis. Gastroenterology. 1990;98:A159.

    Google Scholar 

  75. Miner P, Schwartz J, Aora S et al. Maintenance of remission in ulcerative colitis (UC) patients with controlled-release mesalamine capsules (Pentasa). Gastroenterology. 1992;102:A666.

    Google Scholar 

  76. Mulder CJ, Tytgat GN, Weterman IT et al. Double-blind comparison of slow-release 5-aminosalicylate and sulphasalazine in remission maintenance in ulcerative colitis. Gastroenterology. 1988;95:1449–53.

    PubMed  CAS  Google Scholar 

  77. Rutgeert P with international study group. Comparative efficacy of coated oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1989;3:183–91.

    Article  Google Scholar 

  78. Green JRB, Swan CHJ, Rowlinson AE et al. A three-year prospective study of the maintenance of remission of ulcerative colitis by a new 5-ASA-reIeasing agent, balsalazide. Gastroenterology. 1992;102:A631.

    Google Scholar 

  79. Summers RW, Switz DM, Sessions JT et al. National Cooperative Crohn’s Disease Study: Results of drug treatment. Gastroenterology. 1979;77:847–69.

    PubMed  CAS  Google Scholar 

  80. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H. European Cooperative Crohn’s Disease Study (ECCDS): Results of drug treatment. Gastroenterology. 1984;86:249–66.

    PubMed  CAS  Google Scholar 

  81. Rijk MC, van Hogezand RA, van Lier HJ, van Tongeren JH. Sulphasalazine with prednisone compared with sulphasalazine for treating active Crohn’s disease. Ann Intern Med. 1991;114:445–50.

    PubMed  CAS  Google Scholar 

  82. Rasmussen SN, Binder V, Maier K et al. Treatment of Crohn’s Disease with peroral 5-aminosalicylic acid. Gastroenterology. 1983;85:1350–3.

    PubMed  CAS  Google Scholar 

  83. Barreiro MA, Scagnelli GP, Bank L. The effect of mesalamine (Pentasa) on small bowel Crohn’s disease (SBCD). Gastroenterology. 1991;100:A195.

    Google Scholar 

  84. Piodi LP, Ranzi T, Campanini MC, Vignotti D, Bianchi PA. Open-label prospective study of slow-release 5-aminosalicylic acid 3 g/day per os for mild to moderately active Crohn’s disease (CD) patients. Gastroenterology. 1991;100:A239.

    Google Scholar 

  85. Rasmussen SN, Lauritsen K, Tage-Jensen U et al. 5-Aminosalicylic acid in the treatment of Crohn’s disease. Scand J Gastroenterol. 1987;22:877–83.

    PubMed  CAS  Google Scholar 

  86. Singleton J, Gitnick G, Hanauer S et al. Response of Crohn’s disease to oral Pentasa (controlled-release mesalamine) as a function of disease location and prior therapy: results of a multicenter study. Gastroenterology. 1991;100:A251.

    Google Scholar 

  87. Beck IT, Hudacin J, Paterson WG, Depew WT, Simon JB, Groll A. Mesalazine in the treatment of active Crohn’s disease. Can J Gastroenterol. 1988;2(suppl A):63A-70A.

    Google Scholar 

  88. Scholmerich J, Jenss H, Hartmann F and the German 5-ASA Study Group. Oral 5-aminosalicylic acid (2 g/day) versus 6-methyl-prednisoIone in active Crohn’s disease. Can J Gastroenterol. 1990;4:446–51.

    Google Scholar 

  89. Martin R, Sutherland L, Beck IT et al. Comparative efficacy and safety of oral mesalasine (Salofalk) versus prednisone in the short-term treatment of active Crohn’s disease. A Canadian multicentre controlled trial. Can J Gastroenterol. 1990;4:452–7.

    Google Scholar 

  90. Prantera C, Pallone F, Brunetti G, Cottone M, Miglioli M and the Italian Study Group. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn’s disease. Gastroenterology. 1992;103:363–8.

    PubMed  CAS  Google Scholar 

  91. Brignola C, Iannone P, Pasquali S et al. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn’s disease. Dig Dis Sci. 1992;37:29–32.

    Article  PubMed  CAS  Google Scholar 

  92. Gendre JP, Mary JY, Florent C et al. Does Pentasa prevent relapses of quiescent Crohn’s disease (QCD)? A multicenter placebo controlled trial. Gastroenterology. 1990;98:A171.

    Google Scholar 

  93. International Mesalazine Study Group. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn’s disease. Aliment Pharmacol Ther. 1990;4:55–64.

    Article  Google Scholar 

  94. Schreiber S, Howaldt S, Guth S et al. Maintenance treatment of Crohn’s disease: comparative study of 4-aminosalicylic acid and 5-aminosalicylic acid (Claversal) slow release tablets. Gastroenterology. 1992;102:A692.

    Google Scholar 

  95. Bresci G, Petrucci A, Banti S. 5-Aminosalicylic acid in the prevention of relapses of Crohn’s disease in remission: a long-term study. Int J Clin Pharm Res. 1991;11:200–2.

    CAS  Google Scholar 

  96. Fiasse R, Fontaine F, Vanheuverzwyn R. Prevention of Crohn’s disease recurrences after intestinal resection with Eudragid-L-coated 5-aminosalicylic acid. Preliminary results of a one year double-blind placebo controlled study. Gastroenterology. 1991;100:A208.

    Google Scholar 

  97. Florent C, Cortal A, Quandale P et al. Placebo-controlled trial of Claversal in the prevention of early endoscopie relapse after ‘curative’ resection for Crohn’s disease. Gastroenterology. 1992;102:A623.

    Google Scholar 

  98. Caprilli R, Andreoli A, Capurso L et al. 5-ASA in the prevention of Crohn’s disease post-operative recurrence. Gastroenterology. 1992;102:A601.

    Google Scholar 

  99. Taffet SL, Das KM. Sulphasalazine: adverse events and desensitization. Dig Dis Sci. 1983;28:833–42.

    Article  PubMed  CAS  Google Scholar 

  100. Schroder H, Price-Evans DA. Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut. 1972;13:278–84.

    PubMed  CAS  Google Scholar 

  101. Hanauer SB, Stathopoulos G. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Safety. 1991;6:192–219.

    PubMed  CAS  Google Scholar 

  102. Birnie GG, McLeod TIF, Watkinson G. Incidence of sulphasalazine-induced male infertility. Gut. 1981;22:452–5.

    PubMed  CAS  Google Scholar 

  103. Giaffer MH, O’Brien CJ, Holdsworth CD. Tolerance of three other 5-aminosalicylic acid releasing preparations in sulphasalazine intolerant patients. Gut. 1990;31:A624–5.

    Google Scholar 

  104. Rao SS, Cann PA, Holdsworth CD. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine. Scand J Gastroenterol. 1987,22:332–6.

    PubMed  CAS  Google Scholar 

  105. Burke DA, Manning AP, Williamson JMS, Axon ATR. Adverse reactions to sulphasalazine and 5-aminosalicylic acid in the same patient. Aliment Pharmacol Ther. 1987;1:201–8.

    Article  PubMed  CAS  Google Scholar 

  106. Brogden RN, Sorkin EM. Mesalazine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in chronic inflammatory bowel disease. Drugs. 1989;38:84–105.

    Google Scholar 

  107. Calder IC, Funder CC, Green CR, Harn KN, Tange JD. Nephrotoxic lesion from 5-aminosalicylic acid. Br Med J. 1972;1:152–4.

    Article  CAS  PubMed  Google Scholar 

  108. Norris BH, Korzets Z, Chen P, Bernheim J. Nephrotic syndrome after treatment with 5-aminosalicylic acid. Br Med J. 1988;1:1442.

    Google Scholar 

  109. Tremaine WJ, Schroeder KW. Urinary sediment abnormalities in patients on long term oral 5-aminosalicylic acid (5-ASA) for chronic ulcerative colitis (CUC). Gastroenterology. 1988;94:A465.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Cleveland Clinic Florida, 3000 West Cypress Creek Road, 33309, Fort Lauderdale, Florida, USA

    G. F. Bonner & W. B. Ruderman

Authors
  1. G. F. Bonner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. B. Ruderman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bonner, G.F., Ruderman, W.B. 5-aminosalicylic acid preparations in the treatment of inflammatory bowel disease. Inflammopharmacology 2, 247–262 (1993). https://doi.org/10.1007/BF02660616

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02660616

Keywords

Search

Navigation